Eli Lilly 2010 Annual Report Download - page 114

PROXY STATEMENT
J. Erik Fyrwald
Mr. Fyrwald has a strong record of operational and strategy leadership in two complex worldwide businesses with a
focus on technology and innovation. An engineer by training, he has extensive senior executive experience at DuPont,
a multinational chemical company, where he led their agriculture and nutrition division, which used chemical and
biotechnology solutions to enhance plant health. For the last three years he has been chairman and CEO of Nalco, a
global technology-based water products and services company.
Alfred G. Gilman
Dr. Gilman is a Nobel Prize winning pharmacologist, researcher, and professor. He has deep expertise in basic
science, including mechanisms of drug action, and experience with pharmaceutical discovery research. As the
former dean of a major medical school, he brings to the board important perspectives of both the academic and
practicing medical communities.
R. David Hoover
Mr. Hoover has extensive CEO experience at Ball Corporation, with a strong record of leadership in operations and
strategy. He is an audit committee financial expert as a result of his experience as CEO and CFO of Ball. He also has
extensive corporate governance experience through his service on other public company boards.
Karen N. Horn
Ms. Horn is a former CEO with extensive experience in various segments of the financial industry, including banking
and financial services. Through her for-profit and her public-private partnership work, she has significant
experience in international economics and finance. Ms. Horn has extensive corporate governance experience
through service on other public company boards in a variety of industries.
John C. Lechleiter
Dr. Lechleiter is our chairman, president, and chief executive officer. Under our corporate governance guidelines,
the CEO is expected to serve on the board of directors. Dr. Lechleiter, a Ph.D. chemist, has over 30 years of
experience with the company in a variety of roles of increasing responsibility in research and development, sales and
marketing, and corporate administration. As a result, he has a deep understanding of pharmaceutical research and
development, sales and marketing, strategy, and operations. He also has significant corporate governance
experience through service on other public company boards.
Ellen R. Marram
Ms. Marram is a former CEO with a strong marketing and consumer brand background. Through her nonprofit and
private company activities, she has a special focus and expertise in wellness and consumer health. Ms. Marram has
extensive corporate governance experience through service on other public company boards in a variety of
industries.
Douglas R. Oberhelman
Mr. Oberhelman has a strong strategic and operational background as a senior executive (and most recently as
chairman and CEO) of Caterpillar, a leading manufacturing company with worldwide operations and a special focus
on emerging markets. He is an audit committee financial expert as a result of his prior experience as CFO of
Caterpillar and as a member and chairman of the audit committee of another U.S. public company.
Franklyn G. Prendergast
Dr. Prendergast is a prominent medical clinician, researcher, and academician. He has extensive experience in
senior-most administration at Mayo Clinic, a major medical institution, and as director of its renowned cancer
center. He has special expertise in two critical areas for Lilly—oncology and personalized medicine. As a medical
doctor, he brings an important practicing physician perspective to the board’s deliberations.
Kathi P. Seifert
Ms. Seifert is a retired senior executive of Kimberly-Clark, a global consumer products company. She has strong
expertise in consumer marketing and brand management, having led sales and marketing for several worldwide
brands, with a special focus on consumer health. She has extensive corporate governance experience through her
other board positions.
20